ReviewFrontiers in global women's health2026
Cardiovascular risk prediction in women: rethinking traditional approaches through precision medicine.
Review in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coronary Artery Disease in Women: Sex-Specific Pathophysiology, Risk Factors, Clinical Presentation and Management.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality in women. Estimating cardiovascular risk using prediction models is essential for guiding preventive strategies. Despite progress, conventional risk models still omit critical women-specific factors, limiting their accuracy. Precision medicine, supported by artificial intelligence, provides a framework to integrate these overlooked determinants. This approach may help close existing gaps in cardiovascular risk prediction. Sex-specific biomarkers that contribute to overall cardiovascular risk can be incorporated into risk assessment tools to improve prevention strategies, early detection, and personalized intervention. The integration of imaging-derived variables enhances diagnosis accuracy. Moreover, pharmacokinetic modeling may help optimize therapy and reduce adverse events. Future research should focus on refining risk prediction algorithms that incorporate women-specific cardiovascular risk. Herein, we explore how addressing the burden of CVD in women through precision medicine requires a tailored approach that considers sex-specific risk factors, hormonal influences, biomarkers, and imaging modalities. This review provides a descriptive synthesis of current evidence and highlights existing knowledge gaps and future directions in precision medicine for cardiovascular risk prediction in women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.